News!Real biology intends to go public in Hong Kong

[Dahecai Cube News] On the evening of August 4th, the Hong Kong Stock Exchange, Real Biotechnology Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange.

The prospectus shows that real creatures are a biotechnology company that drives R & D as a driving force, and is committed to innovative drugs for developing, manufacturing and commercial treatment of viral, tumors and cerebrovascular diseases. Its core product Azf is definitely a pyrine nucleoside, which has a broad -spectrum antiviral activity.

Azf is scheduled to be approved by the State Drug Administration for the treatment of adult COVID-19 in July 2022. Azf is the first oral direct antiviral drug approved by the State Drug Administration for the treatment of COVID-19 by the State Drug Administration.

On July 25, 2022, Henan Real Biotechnology Co., Ltd. and Fosun Pharmaceutical's Affiliated Company Fosun Pharmaceutical Industry reached a strategic cooperation agreement on the joint development of Azfdin and the exclusive commercialization of Fosun Pharmaceutical Industry.

The prospectus also mentioned that the real creature has a production plant in Pingdingshan, Henan Province, with a total construction area of ​​about 22,262 square meters. The production plant has recently started operations, with an annual production capacity of about one billion tablets Azfding.

Responsible editor: Chen Yuyao | Review: Li Zhen | Director: Wan Junwei

- END -